Advertisement
Organisation › Details
Medigene (Group)
Medigene AG (FSE: MDG1) is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product enhancement and product development technologies, allows Medigene to create best-in-class differentiated, T Cell Receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit medigene.com About Medigene’s TCR-T Therapy Platform Medigene’s immunotherapies help activate the patient’s own defense mechanisms by harnessing T cells in the battle against cancer. Medigene’s end-to-end platform combines multiple exclusive and proprietary technologies to create best-in-class TCR-T therapies. The platform includes multiple product enhancement technologies, (e.g. PD1-41BB Switch Receptor, Precision Pairing) and development optimization technologies (e.g. Allogeneic-HLA (Allo-HLA) TCR Priming) to aid the development of differentiated TCR-T therapies. Partnerships with multiple companies including BioNTech, 2SeventyBio, and Hongsheng Sciences, continue to validate the platform’s assets & technologies. About Medigene’s MDG1015 Program MDG1015 is a 3rd generation T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1, a well-recognized and validated cancer testis antigen which is expressed in multiple tumor types. MDG1015 contains our high-avidity, NY-ESO-1 TCR combined with our proprietary PD1-41BB co-stimulatory switch receptor that blocks the PD1/PD-L1 inhibitory axis while simultaneously activating the T cell through the well described -41BB pathway further enhancing the activity and persistence of the TCR-T in the hostile tumor microenvironment (TME). MDG1015 is currently undergoing IND/CTA enabling studies. *
Start | 1994-01-01 established | |
Industry | biopharmaceutical | |
Person | Schendel, Dolores J. (Medigene 202207– CSO + Head of RnD before CEO + CMO + Triant + HelmholtzZentrum München) | |
Street | 11 Lochhamer Str. | |
City | 82152 Martinsried | |
Tel | +49-89-8565-2900 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | C: 51 to 100 (2020-12-31) |
Currency | EUR | |
Annual sales | 31,247,000 (revenue, consolidated (2022) 2022-12-31) | |
Profit | -8,330,000 (2022-12-31) | |
Cash | 22,224,000 (2022-12-31) | |
* Document for »About Section«: Medigene AG. (2/1/23). "Press Release: Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications". Planegg. | ||
Record changed: 2023-12-30 |
Advertisement
More documents for Medigene (Group)
- [1] Medigene AG. (12/19/18). "Press Release: Medigene Publishes Topline Interim Data from Ongoing Phase I/II Clinical Trial with DC Vaccines in AML Patients". Martinsried....
- [2] Medigene AG. (8/3/17). "Press Relase: Medigene Reports Results of First Six Months 2017". Planegg....
- [3] Medigene AG. (3/28/17). "Press Release: Medigene Announces Participation at Six National and International Conferences". Planegg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top